Recent advances in molecular profiling have enhanced our understanding of glioma biology and improved patient stratification based on biomarkers such as isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion, TERT promoter mutation, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation [2]. This evidence concerns the gene MGMT and central nervous system cancer.